1. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
- Author
-
Mette C. Jørgensen, Theis Aagaard, Joanne Reekie, Gedske Daugaard, Marie Helleberg, Henrik Sengeløv, Jens D Lundgren, Lena Specht, Ashley Roen, and Amanda Mocroft
- Subjects
Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,lcsh:RC254-282 ,law.invention ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Risk Factors ,Interquartile range ,law ,Neoplasms ,Intensive care ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,cancer ,Radiology, Nuclear Medicine and imaging ,Hospital Mortality ,Poisson regression ,Risk factor ,Aged ,Retrospective Studies ,Original Research ,business.industry ,Absolute risk reduction ,Clinical Cancer Research ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,medicine.disease ,mortality ,Intensive care unit ,infection ,Hospitalization ,Survival Rate ,Intensive Care Units ,febrile neutropenia ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,symbols ,Female ,business ,Complication ,Febrile neutropenia ,Follow-Up Studies - Abstract
Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk., Febrile neutropenia (FN) is a severe complication to chemotherapy. However, associations between FN and longer term clinical outcomes are poorly elucidated. Among 9018 patients with solid cancers followed for 18 775 person‐years after initiating first‐line chemotherapy FN was associated with increased risk of all‐cause and infectious mortality and risk of intensive care unit admissions. A range of risk factors at the time of FN were found that identified a subgroup of patients carrying a grave prognosis.
- Published
- 2020
- Full Text
- View/download PDF